Eterna Therapeutics Inc
Change company Symbol lookup
Select an option...
ERNA Eterna Therapeutics Inc
BAC Bank of America Corp
BSRR Sierra Bancorp
MSI Motorola Solutions Inc
ESI Element Solutions Inc
INVZW Innoviz Technologies Equity Warrant Exp 05 April 2026 *W EXP 04/05/2026
BEN Franklin Resources Inc
FLFG Federal Life Group Inc
GIIXU Gores Holdings VIII Inc
AEE Ameren Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Eterna Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing advanced therapies using Messenger RNA (mRNA) cell engineering technology. The Company is engaged in developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its product pipeline is based on patented foundational mRNA cell engineering technology and offers multiple clinical applications with future sub-licensing and partnering opportunities. It formulates mRNA using lipid nanoparticle (LNP) technology. The ToRNAdo delivery system surrounds and protects the mRNA cargo, enabling delivery into human cells. The Company has licensed a portfolio of over 100 patents covering key cell engineering technologies, including therapeutic gene editing in clinical development. It has multiple cell and gene-editing therapies in preclinical development for various indications.

The symbol you entered, BTX, changed to ERNA.

Price
Delayed
$3.63
Day's Change
0.53 (17.10%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.63
Day's Low
3.36
Volume
(Heavy Day)

Today's volume of 23,862 shares is on pace to be much greater than ERNA's 10-day average volume of 8,100 shares.

23,862

Company Profile

Eterna Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing advanced therapies using Messenger RNA (mRNA) cell engineering technology. The Company is engaged in developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its product pipeline is based on patented foundational mRNA cell engineering technology and offers multiple clinical applications with future sub-licensing and partnering opportunities. It formulates mRNA using lipid nanoparticle (LNP) technology. The ToRNAdo delivery system surrounds and protects the mRNA cargo, enabling delivery into human cells. The Company has licensed a portfolio of over 100 patents covering key cell engineering technologies, including therapeutic gene editing in clinical development. It has multiple cell and gene-editing therapies in preclinical development for various indications.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.03x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
60.5K
Previous Month
53.2K
Percent of Float
3.56%
Days to Cover
1.7140 Days

Share Information

ERNA is in a share class of common stock
Float
1.7M
Shares Outstanding
2.9M
Institutions Holding Shares
47
16.70%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Charles Cherington
  • Matthew AngelPres.
  • Andrew JacksonCFO
  • Jay SialChief Admin.
  • Sandra Gurrola

Address

  • 10355 Science Center Drive, Suite 150
  • San Diego, CA 92121
  • Phone: (212) 582-1199
  • Fax: (302) 655-5049
  • https://eternatx.com/

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.